luciddx.com - Rasio total nilai perusahaan marang pendapatan LUCD

Lucid Diagnostics Inc. (LUCD) management effectively engages with insurance companies, ensuring data transparency for EsoGuard. Business revenues are based on the sale of diagnostic tests for precancerous esophageal conditions to patients with GERD. Scaling analysis systems creates a foundation for stable growth. The EV/Sales valuation demonstrates price dynamics relative to revenue, where 14788.60 determines the latest valuation metric.
Lucid Diagnostics, Inc - rincian analitis lan metrik utama (LUCD)

Analyzing the enterprise value-to-revenue ratio on GURU.Markets, we determine the market status of Lucid Diagnostics Inc. (LUCD) within the diagnostics sector. This indicator compares the total value of the business against its revenues, eliminating the impact of debt loads and tax distortions. The metric measures the capitalization efficiency of each unit of revenue. However, the geopolitical fragmentation of healthcare limits test exports, creating pressure on this ratio. The stability of the chart confirms current resilience but limits expansion potential.